US EditionNovo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
UNITED STATES, JUN 24 – Novo Nordisk ended its April 2025 partnership with Hims & Hers after the telehealth company sold unapproved, unsafe knockoffs of Wegovy, causing Hims & Hers shares to drop 35%.
- On June 23, 2025, Novo Nordisk announced it would discontinue its partnership with Hims & Hers Health, Inc. due to concerns over the telehealth company's promotion and sale of counterfeit versions of Wegovy.
- The termination occurred after Novo Nordisk determined that Hims & Hers violated legal restrictions by distributing large quantities of compounded medications while misrepresenting them as individualized treatments.
- Novo Nordisk accused Hims & Hers of deceptive marketing that endangers patient safety by promoting unapproved semaglutide products made with foreign illicit ingredients.
- Shares of Hims & Hers dropped close to 30% during morning trading following the announcement, while Novo Nordisk emphasized its dedication to supplying genuine, FDA-approved Wegovy through reputable telehealth partners.
- The termination highlights regulatory challenges in the weight loss drug market and suggests Novo Nordisk will continue acting to protect patients from unsafe compounded products.
129 Articles
129 Articles
Compounding Breaks Up Novo Nordisk-Hims & Hers Partnership
As GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs that promise to have similar effects at a much lower cost. The appeal of that isn’t hard to see — but the lack of regulation has led some users of the compounded versions to fall ill, leading the FDA to clarify its policies earlier this year. Now, compounding is at the center of a dispute between pharmaceutical company No…
Hims & Hers' ugly split with Wegovy maker weighs on the telehealth company's future
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.
HIMS & HERS HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ...
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of…
HIMS & HERS HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims on Behalf of Investors of Hims & Hers Health, Inc. - HIMS - Hims & Hers Health (NYSE:HIMS)
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE:HIMS). The investigation concerns whether Hims & Hers Health and certain of its officers and/or directors have engaged in fraud, negligence or other unlawf…
The Conway Daily Sun
Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
PHILADELPHIA, June 24, 2025 /PRNewswire/ -- Berger Montague, a nationally recognized securities litigation firm, is investigating potential claims on behalf of investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company")…
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
